Infantile Neuroaxonal Dystrophy (INAD) is a sub type of PLAN (phospholipase associated neurodegeneration) that affects approximately 5200 children globally. It starts to present between 6 months and 3 years of age. There is currently no treatment that can stop or slow the progression for children suffering from this devastating, neurodegenerative disease, but with your help, we can change that. With a life expectancy of 5-10 years, gene therapy is the only hope for saving the lives of children afflicted with INAD/PLA2G6 related disorders.